MarketBeat estimates November 3 results for Heron Therapeutics stock

Published on 10/20/2026 at 19:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Heron posted Q2 revenue of USD 37.70 million for June 30, 2026. Heron Therapeutics stock was USD 0.37 on October 20, 2026 versus USD 0.36.

Reporting date and revenue trend

MarketBeat estimated a November 3, 2026 results date for Heron Therapeutics on October 19, 2026.
Six-month 2026 revenue was USD 72.38 million, down 4.90 percent from USD 76.10 million in 2025.
Heron Therapeutics stock was at EUR 0.33 at Lang & Schwarz on October 20, 2026 at 7:39 p.m. CEST.

HRTX, US4277461020, Illustration mit AI erstellt.

MarketBeat estimated on October 19, 2026 that Heron Therapeutics would report third-quarter 2026 results on November 3, 2026 before the market opens. The date puts the next earnings test within two weeks, while the latest six-month figures point to a tougher revenue comparison. Heron Therapeutics stock was trading at EUR 0.33 at Lang & Schwarz on October 20, 2026 at 7:39 p.m. CEST.

Six-month revenue fell 4.90 percent

Heron reported USD 72.38 million in revenue for the six months ended June 30, 2026, compared with USD 76.10 million in the same period of 2025. According to Heron Therapeutics on August 10, 2026, acute-care revenue rose 38.20 percent to USD 28.96 million, while oncology revenue fell 21.30 percent to USD 43.42 million.

The company also withdrew its full-year 2026 net product sales and adjusted EBITDA guidance in the same release. That change leaves the November report focused on product sales, cash use and the balance between acute-care growth and oncology pressure.

HRTX remains far below its yearly high

Heron Therapeutics had a market capitalization of USD 69.8 million and traded at USD 0.37 on Nasdaq on October 20, 2026 at 1:42 p.m. ET. The quote was USD 0.11 above the 52-week low of USD 0.26 and USD 1.21 below the 52-week high of USD 1.58, leaving the stock 76.58 percent below that high. Trading volume reached 1,066,368 shares.

November 3 carries the next test

MarketBeat listed November 3, 2026 as the estimated third-quarter reporting date, before market open, with an 8:30 a.m. ET conference call. Its estimate calls for USD 37.50 million in revenue and a loss of USD 0.03 per share, versus USD 38.21 million and a loss of USD 0.05 per share in the year-earlier quarter.

The valuation remains loss-based: the price-to-earnings ratio was negative 1.94 on October 20, 2026, while the trailing dividend yield was zero percent. Heron's latest release reported a second-quarter net loss of USD 5.49 million and cash, cash equivalents and short-term investments of USD 42.7 million as of June 30, 2026.

Stock price and investor context

The euro quotation places Heron Therapeutics in the penny-stock segment for German investors, while the Nasdaq quotation provides the primary-market context. The next dated operating milestone is the estimated November 3 report, where the revenue comparison will test whether acute-care growth can offset weaker oncology sales.

Heron Therapeutics was trading at EUR 0.33 at Lang & Schwarz on October 20, 2026 at 7:39 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Heron Therapeutics stock.